Immediate Impact

20 from Science/Nature 58 standout
Sub-graph 1 of 22

Citing Papers

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2024 Standout
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
2021 Standout
27 intermediate papers

Works of Michael O. Montgomery being referenced

Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States
2012
Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial
2010

Author Peers

Author Last Decade Papers Cites
Michael O. Montgomery 433 164 122 434 253 9 806
Aurélie Guguin 280 484 39 124 158 7 888
K Illingworth 177 122 21 108 83 16 750
Kenneth O. Rothaus 353 189 8 169 66 19 978
Claudia Specchia 91 402 58 109 182 22 894
Sevim Barbasso Helmers 67 171 24 145 685 17 865
Stuart M. Levine 73 276 23 83 413 21 945
Jan Jernbeck 466 65 34 99 22 22 709
Xiaoqiang Han 100 210 171 50 75 23 926
Brian P. Lipsky 130 212 14 118 44 10 832
Abraham Menahem Nahir 240 93 66 41 51 17 785

All Works

Loading papers...

Rankless by CCL
2026